Tarlatamab is a bispecific T-cell engager that binds to DLL3 expressed on the surface of tumor cells and CD3 expressed on the surface of T-cells.

Our data clearly show that it is feasible and safe to implement stepwise acceleration of nivolumab and pembrolizumab administration to a 10-minute infusion time,” the researchers wrote.

A vomiting-free ward protocol significantly reduced the effects of nausea and vomiting on QOL, anxiety, and depression, in patients with gynecologic cancers receiving chemotherapy.

Repeat biopsies in patients with TNBC may detect changes in HER2 status and allow more patients to gain access to T-DXd, data suggest.

Researchers sought to assess the access to CAR-T therapy for patients within community-based and transplant cell therapy networks.

Medical staff and patients with CRC reported that intermittent symptom management did not provide sufficient support to patients at home.

DNA detection at baseline was associated with worse recurrence-free, overall survival in BRAFV600-mutant stage III melanoma.

Until prospective data are available, researchers recommend that patients with ER-low breast cancer “should be counseled regarding the potential benefit” of adjuvant endocrine therapy.

Childhood cancer survivors “may experience considerable accelerated aging throughout their lifespan,” the researchers wrote.

Investigators assessed whether a reported survival disadvantage in men with secondary rectal cancer following prostate cancer radiation therapy vs primary rectal cancer is due to patient ...

Discrepancies between clinical and pathologic staging of muscle-invasive bladder cancer (MIBC) are found in three-quarters of patients following radical cystectomy without neoadjuvant therapy, ...

Patients with CLL and a CSHA CFS score greater than 3 had significantly higher rates of treatment interruption due to adverse effects.